Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated…
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines…
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris Patient Enrollment at 58 Patients…
-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential…
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and…
CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a…
SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that…
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for…
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash…
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted…